SEARCH

SEARCH BY CITATION

References

  • 1
    Van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008; 71: 10016.
  • 2
    Thompson IM. Flare associated with LHRH-agonist therapy. Rev. Urol. 2001; 3 (Suppl 3): S1014.
  • 3
    Tombal B, Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur. Urol. Suppl. 2005; 4: 306.
  • 4
    Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. 2007; 178: 12905.
  • 5
    Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr. Oncol. 2010; 17 (Suppl 2): S729.
  • 6
    Chi KN, Bjartell A, Dearnaley D et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur. Urol. 2009; 56: 594605.
  • 7
    Heidenreich A, Bolla M, Joniau S et al. 2011. Guidelines on prostate cancer. [Cited 8 August 2011.] Available from URL: http://www.uroweb.org/gls/pdf/08_Prostate_Cancer.pdf
  • 8
    Sharifi N, Dahut WL, Steinberg SM et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005; 96: 9859.
  • 9
    Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int. 2005; 96 (Suppl 2): 416.
  • 10
    Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin. Proc. 2007; 82: 2439.
  • 11
    Mahon KL, Henshall SM, Sutherland RL et al. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr. Relat. Cancer 2011; 18: R10323.
  • 12
    Guyton AC. Reproductive and hormonal functions of the male. In: Guyton AC (ed.). Textbook of Medical Physiology, 8th edn. WB Saunders Company, Philadelphia, PA, 1991; 88598.
  • 13
    Sharma OP, Weinbauer GF, Behre HM, Nieschlag E. The gonadotropin-releasing hormone (GnRH) agonist-induced initial rise of bioactive LH and testosterone can be blunted in a dose-dependent manner by GnRH antagonist in the non-human primate. Urol. Res. 1992; 20: 31721.
  • 14
    Princivalle M, Broqua P, White R et al. Rapid suppression of plasma testosterone levels and tumor growth in the Dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J. Pharmacol. Exp. Ther. 2007; 320: 111318.
  • 15
    Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin. Pharmacother. 2004; 5: 21719.
  • 16
    Van Poppel H, Tombal B, de la Rosette JJ et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-year, multicentre, randomised, phase II dose-finding study in the treatment of prostate cancer. Eur. Urol. 2008; 54: 80515.
  • 17
    Gittelman M, Pommerville PJ, Persson BE et al. A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J. Urol. 2008; 180: 198692.
  • 18
    Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102: 15318.
  • 19
    Crawford ED, Tombal B, Miller K et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 2011; 186: 88997.
  • 20
    McLeod D, Zinner N, Tomera K et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 75661.
  • 21
    Selvaggi F, Khoe GSS, Van Cangh P et al. Comparison of abarelix depot (A-D) and goserelin (G) plus bicalutamide (B) in advanced prostate cancer: results of a multicentre, open-label, randomised, phase III study. Eur. Urol. 2001; 39 (Suppl 5): 78 (abstract #303).
  • 22
    Tomera K, Gleason D, Gittelman M et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J. Urol. 2001; 165: 15859.
  • 23
    Trachtenberg J, Gittleman M, Steidle C et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol. 2002; 167: 16704.
  • 24
    Plenaxis Drug Information. 2011. [Cited 8 August 2011]. Available from URL: http://www.rxlist.com/plenaxis-drug.htm#
  • 25
    Williams SG, Duchesne GM, Millar JL et al. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004; 60: 10827.
  • 26
    Hussain M, Tangen CM, Higano C et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 2006; 24: 398490.
  • 27
    Hussain M, Goldman B, Tangen C et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 2009; 27: 24506.
  • 28
    Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a Phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 2010; 57: 83642.
  • 29
    Miller K, Rüssel C, Gobel S et al. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). Eur. Urol. Suppl. 2010; 9: 76 (abstract 140).
  • 30
    Beer TM, Ryan C, Bhat G et al. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anticancer Drugs 2006; 17: 10759.
  • 31
    Beer TM, Garzotto M, Eilers KM et al. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J. Urol. 2003; 169: 173841.
  • 32
    Boccon-Gibod L, van der Meulen E, Persson B-E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther. Adv. Urol. 2011; 3: 12740.
  • 33
    Hanninen M, Venner P, North S. A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can. Urol. Assoc. J. 2009; 3: 36974.
  • 34
    Lin GW, Yao XD, Zhang SL et al. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J. Androl. 2009; 11: 44350.
  • 35
    US Food and Drug Administration. 2010. GnRH agonists: label change – increased risk of diabetes and cardiovascular disease (update). [Cited 8 August 2011]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm230359.htm
  • 36
    Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AA. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J. Urol. 2010; 184: 231319.
  • 37
    Smith MR, Klotz L, van der Meulen E, Colli E, Tankó L. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analyses of prospective clinical trials of degarelix. J. Urol. 2011; 186: 183542.
  • 38
    Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol. 2006; 2: 67796.
  • 39
    Huhtaniemi I, White R, McArdle CA, Persson BE. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol. Metab. 2009; 20: 4350.
  • 40
    Waknine Y. 2005. International approvals: plenaxis, tostrex, troxatyl. [Cited 8 August 2011]. Available from URL: http://www.medscape.com/viewarticle/513892
  • 41
    Specialty European Pharma. 2011. Your partner in urology. [Cited 8 August 2011]. Available from URL: http://www.specialityeuropeanpharma.com
  • 42
    Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J. Pharmacol. Exp. Ther. 2002; 301: 95102.
  • 43
    Koechling W, Hjortkjaer R, Tankó LB. Degarelix, a novel gonadotrophin-releasing hormone blocker, causes minimal histamine release in vitro compared with cetrorelix, abarelix and ganirelix. Br. J. Clin. Pharmacol. 2010; 70: 5807.
  • 44
    Schröder FH, Tombal B, Miller K et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010; 106: 1827.
  • 45
    Anderson J, Al-Ali G, Wirth M et al. Improved relief of lower urinary tract symptoms (LUTS) with a gonadotrophin-releasing hormone (GnRH) blocker compared with an agonist + antiandrogen (AA) in an open-label, randomised study (CS28). Abstract presented at the European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain, 2011.